Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash & Equivalents: 2014-2024

Historic Cash & Equivalents for KalVista Pharmaceuticals (KALV) over the last 8 years, with Dec 2024 value amounting to $182.3 million.

  • KalVista Pharmaceuticals' Cash & Equivalents was N/A to $182.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $182.3 million, marking a year-over-year change of. This contributed to the annual value of $31.8 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q4 2024, KalVista Pharmaceuticals' Cash & Equivalents is $182.3 million, which was up 338.48% from $41.6 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' Cash & Equivalents' 5-year high stood at $182.3 million during Q4 2024, with a 5-year trough of $15.8 million in Q2 2020.
  • Over the past 2 years, KalVista Pharmaceuticals' median Cash & Equivalents value was $41.6 million (recorded in 2024), while the average stood at $59.7 million.
  • Data for KalVista Pharmaceuticals' Cash & Equivalents shows a maximum YoY plummeted of 66.96% (in 2020) over the last 5 years.
  • Over the past 4 years, KalVista Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $16.2 million in 2020, then decreased by 4.77% to $17.7 million in 2021, then reached $57.7 million in 2023, then declined by 27.89% to $182.3 million in 2024.
  • Its Cash & Equivalents stands at $182.3 million for Q4 2024, versus $41.6 million for Q4 2024 and $31.8 million for Q3 2024.